PSENEN
ENSG00000205155
Target class
Enzyme
Chromosome
19
Approved drugs
2
Clinical candidates (approved and in development)
7
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Other names
- PEN2
- Target name
- PSENEN
- Gene name
- Presenilin enhancer, gamma-secretase subunit
- Gene symbol
- PSENEN
- Protein name
- Gamma-secretase subunit PEN-2 (Presenilin enhancer protein 2)
- Gene biotype
- Protein coding
- Gene family
- Gamma-secretase complex subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 189.44
- Tissue specificity (Gini)
- 0.202
- Tissue specificity (tau)
- 0.79
- KEGG gene identifiers
- hsa:55851
- Protein interaction confidence
- 0.8807
- Protein interaction partners
- 20
- R-HSA-1251985
- R-HSA-193692
- R-HSA-205043
- R-HSA-2122948
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-2979096
- R-HSA-3928665
- R-HSA-9013507
- R-HSA-9013700
- R-HSA-9017802
- R-HSA-977225
- R-HSA-9839383
- End position
- 35747519
- Start position
- 35745070
- Chromosome
- 19
- Strand
- Forward
- Endoplasmic reticulum membrane
- Multi-pass membrane protein . Golgi apparatus, Golgi stack membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Membrane
- Multi-pass membrane protein . Note=Predominantly located in the endoplasmic reticulum and in the cis-Golgi. .
- PubMed 12522139
- PubMed 12639958
- PubMed 25043039
- PubMed 26280335
- PubMed 26623517
- PubMed 30598546
- PubMed 30630874
- PubMed 24941111
- PubMed 12198112
- Tissue specificity (tau)
- 0.789713
- Expression inequality (Gini)
- 0.201703
Expression in transcripts per million
- Testis
- 189.44
- Thyroid
- 64.52
- Cervix - Endocervix
- 58.98
- Pituitary
- 56.46
- Whole Blood
- 55.45
Expression in transcripts per million
- Testis189.44
- Thyroid64.52
- Cervix - Endocervix58.98
- Pituitary56.46
- Whole Blood55.45
- Cells - Cultured fibroblasts53.88
- Lung52.58
- Fallopian Tube52.5
- Nerve - Tibial52.38
- Cervix - Ectocervix50.82
- Brain - Spinal cord (cervical c-1)50.8
- Kidney - Medulla50.63
- Uterus49.9
- Esophagus - Mucosa49.19
- Spleen48.93
- Artery - Coronary46.34
- Artery - Aorta45.34
- Breast - Mammary Tissue45.01
- Prostate44.97
- Adrenal Gland44.92
- Vagina44.5
- Adipose - Visceral (Omentum)42.43
- Bladder42.05
- Adipose - Subcutaneous41.38
- Ovary41.19
And 29 more, listed on the interactive page.
- GO:0006509
- GO:0007220
- GO:0010950
- GO:0016485
- GO:0031293
- GO:0034205
- GO:0042982
- GO:0042987
- GO:0005783
- GO:0005789
- GO:0005794
- GO:0005886
- GO:0010008
- GO:0016020
- GO:0070765
- GO:0005515
- GO:0019899
- GO:0061133
Related records
Trials (117)
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
- A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
- A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
- A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
- A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
- A Study of Semagacestat for Alzheimer's Patients
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- A Trial In Patients With Advanced Cancer And Leukemia
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
- Acute Dose-dependent Effects of DMT in Healthy Subjects
Drugs (7)
- Avagacestat Gamma-secretase inhibitor
- Begacestat Gamma-secretase inhibitor
- Nirogacestat Gamma-secretase inhibitor
- Nirogacestat hydrobromide Gamma-secretase inhibitor
- RG-4733 Gamma-secretase inhibitor
- Semagacestat Gamma-secretase inhibitor
- Tarenflurbil Gamma-secretase modulator